Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States
Jia, X., Zhao, Y., Carrico, J., Brodtkorb, T-H., Mendelsohn, A., Lowry, S., Feldman, S., Wu, JJ., & Armstrong, A. (2018). Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States. Journal of managed care & specialty pharmacy, 24(10-a Suppl), S79. https://doi.org/10.18553/jmcp.2018.24.10-a.s1
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.